Faeth Therapeutics, Inc. (FTH) Free cash flow
- Free cash flow · 12 months (USD): Value $-33.86M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-33.86M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-33.86M − $6.00K ≈ $-33.86M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-33.86M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.17× | Operating cash flow / net income. Period ending 2026-06-30. $-33.86M ÷ $-195.53M ≈ 0.17× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -33.86M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 6.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -33.86M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -195.53M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-33.86M | (m) | $-33.86M | $6.00K | (m) | (m) | (m) | $-195.53M | (m) | (m) | (m) | 0.17× |
| 2026-03-31 | $-24.11M | (m) | $-24.09M | $22.00K | (m) | (m) | (m) | $-184.46M | (m) | (m) | (m) | 0.13× |
| 2025-12-31 | $-20.47M | (m) | $-20.45M | $16.00K | (m) | (m) | (m) | $-21.09M | (m) | (m) | (m) | 0.97× |
| 2025-09-30 | $-22.40M | (m) | $-22.38M | $16.00K | (m) | (m) | (m) | $-24.14M | (m) | (m) | (m) | 0.93× |
| 2025-06-30 | $-24.28M | (m) | $-24.27M | $16.00K | (m) | (m) | (m) | $-26.82M | (m) | (m) | (m) | 0.90× |
| 2025-03-31 | $-24.26M | (m) | $-24.15M | $109.00K | (m) | (m) | (m) | $-29.03M | (m) | (m) | (m) | 0.83× |
| 2024-12-31 | $-24.82M | (m) | $-24.67M | $146.00K | (m) | (m) | (m) | $-30.16M | (m) | (m) | (m) | 0.82× |
| 2024-09-30 | $-25.19M | (m) | $-25.04M | $146.00K | (m) | (m) | (m) | $-29.80M | (m) | (m) | (m) | 0.84× |
| 2024-06-30 | $-24.38M | (m) | $-24.23M | $146.00K | (m) | (m) | (m) | $-29.67M | (m) | (m) | (m) | 0.82× |
| 2024-03-31 | $-27.97M | (m) | $-27.90M | $66.00K | (m) | (m) | (m) | $-31.92M | (m) | (m) | (m) | 0.87× |
| 2023-12-31 | $-32.20M | (m) | $-32.02M | $180.00K | (m) | (m) | (m) | $-34.10M | (m) | (m) | (m) | 0.94× |
| 2023-09-30 | $-35.61M | (m) | $-35.43M | $180.00K | (m) | (m) | (m) | $-38.92M | (m) | (m) | (m) | 0.91× |
| 2023-06-30 | $-38.01M | (m) | $-37.58M | $430.00K | (m) | (m) | (m) | $-45.21M | (m) | (m) | (m) | 0.83× |
| 2023-03-31 | $-40.47M | (m) | $-40.01M | $453.00K | (m) | (m) | (m) | $-46.36M | (m) | (m) | (m) | 0.86× |
| 2022-12-31 | $-39.35M | (m) | $-39.03M | $321.00K | (m) | (m) | (m) | $-48.59M | (m) | (m) | (m) | 0.80× |
| 2022-09-30 | $-38.18M | (m) | $-37.32M | $856.00K | (m) | (m) | (m) | $-45.72M | (m) | (m) | (m) | 0.82× |
| 2022-06-30 | $-37.09M | (m) | $-36.09M | $994.00K | (m) | (m) | (m) | $-41.99M | (m) | (m) | (m) | 0.86× |
| 2022-03-31 | $-31.80M | (m) | $-30.24M | $1.56M | (m) | (m) | (m) | $-41.23M | (m) | (m) | (m) | 0.73× |
| 2021-12-31 | $-32.28M | (m) | $-30.26M | $2.03M | (m) | (m) | (m) | $-36.79M | (m) | (m) | (m) | 0.82× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-18.91M | (m) | $-17.70M | $1.21M | (m) | (m) | (m) | $-20.10M | (m) | (m) | (m) | 0.88× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |